Beijing, March 18, 2015 -- Agilent Technologies Inc. announced that its chairman and chief operating officer, Mike McMullen, has been appointed by the board of directors to be the CEO of Agilent, with immediate effect. This new appointment is part of Agilent's previously announced CEO succession plan. Former CEO William (Bill) Sullivan will continue to serve as a company consultant until October 31, 2015, when he will officially retire.
James G. Cullen, Chairman of the Agilent Board of Directors, said: “Bill Sullivan has performed exceptionally well during his ten-year tenure. Under his leadership, the company has successfully transformed from a multi-technology company into a professional leader in the life sciences, diagnostics and application markets. ."
McMullen, 53, is the third president and CEO of Agilent Technologies since its separation from HP in 1999. He has been with Agilent and HP for more than 30 years.
Cullen said: "Mike McMullen has created a strong momentum for the company's development. Since he was appointed as the CEO of the appointment six months ago, he has created a new organizational structure and developed a strong development strategy to actively promote the company's growth and shareholder Create value."
McMullen said: "I am looking forward to Agilent's future and I am excited to be able to lead such an outstanding Agilent staff team. We are well positioned to take advantage of new opportunities in the life sciences and diagnostics market. In addition, the recently established Agilent CrossLab Group It also helps us to serve our customers in a more comprehensive and coherent way. We have made great progress in this regard."
McMullen also said: "I am very honored to lead Agilent and our outstanding team to continue, we will actively develop various solutions to help our customers meet the major challenges of the future world."
McMullen joined Hewlett-Packard (predecessor of Agilent) in 1984 as a financial analyst for the Analytical Products Group and held senior positions in various positions. From 2009 to 2014, he served as President of the Agilent Chemical Analysis Group, responsible for the energy, chemical, food safety and environmental markets, as well as the services and consumables business of the Chemical Analysis and Life Sciences Group.
In September 2014, Mike McMullen was appointed President and Chief Operating Officer and CEO of the company. During his tenure, he oversaw the company's three business units (Life Sciences and Applications Markets Group, Agilent CrossLab Group and Diagnostics and Genomics Group), order fulfillment, and global organizations including IT, workplace services, global sourcing and logistics.
The characteristics of POCT devices determine that they can play an important role in primary medical institutions. In order to standardize and strengthen the application of on-site rapid testing in primary medical and health institutions, promote the rational allocation, safe and effective use of POCT in primary medical and health institutions, give full play to its use value, and ensure the healthy development of medical and health services, "On-site Point-of-care Testing (POCT) Primary The Expert Consensus on the Application of Medical and Health Institutions (hereinafter referred to as the "Consensus") came into being. The consensus was published in the 2019 "China Medical Equipment" magazine after first draft writing, 2 expert on-site discussions, 2 expert online review meetings, and 3 submission revisions. The formulation of the consensus will greatly promote the management standards of the POCT industry, continuously increase the training of grass-roots personnel, deeply understand the application requirements of POCT at the grass-roots level, and promote the rapid development of the POCT industry.
Point-of-care testing (POCT) represents a fruitful method in today's hospitals in terms of patient care and cost management. Its application enables some of the testing items originally undertaken by the central laboratory to be transferred to the clinical departments and patient beds that need it. side. For blood gas analysis technology, POCT has shown great advantages.
Our blood gas analyzer is small and portable, beautiful in appearance, accurate in results and good in stability. It is a blood gas analysis platform with both appearance and strength. It can be used not only in the central laboratory department, but also at the bedside of patients to meet the bedside detection needs of clinical departments such as hospital ICU, emergency, anesthesia, respiratory, neurology, etc. It realizes true POCT blood gas analysis and provides more advantageous assistance for clinical practice. Diagnostic Services.
Portable Analyzer for Blood Fat,Home Care Blood Glucose Meter,Best Blood Glucose Meter,Blood Glucose Meter Device
Jilin Sinoscience Technology Co. LTD , https://www.jlgkscience.com